Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.49
-0.05 (-0.90%)
At close: Oct 21, 2025, 4:00 PM EDT
5.43
-0.06 (-1.07%)
After-hours: Oct 21, 2025, 7:59 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
301.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 125.00K | - | - |
Dec 31, 2021 | 125.00K | - | - |
Dec 31, 2020 | 125.00K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CADL News
- 5 days ago - Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board - GlobeNewsWire
- 7 days ago - Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - GlobeNewsWire
- 7 days ago - Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - PRNewsWire
- 7 days ago - Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine - GlobeNewsWire
- 8 days ago - Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha
- 18 days ago - Candel Therapeutics to Present at the SITC 2025 Annual Meeting - GlobeNewsWire
- 22 days ago - Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewsWire